In an effort aimed at encouraging earlier diagnosis and even potentially prevention for Type 1 diabetes, the JDRF and the American Diabetes Association have published a new evaluation of the presymptomatic staging of Type 1 diabetes.
DexCom made a big splash last quarter when it launched a marketing campaign featuring teen pop idol Nick Jonas, who has Type 1 diabetes. The move to address its significant pediatric market helped the connected continuous glucose monitor company to new revenue heights--up 59% to $93.2 million in the second quarter as compared to a year ago.
Canadian researchers have found that the dual-hormone artificial pancreas works best for treating patients with Type 1 diabetes by reducing the amount of time they are exposed to nocturnal hypoglycemia.
Becton Dickinson worked with diabetes patient advocate groups to develop its latest insulin infusion set, which is designed for improved insulin flow with reduced interruptions. Now the FDA has cleared the new infusion set based on BD FlowSmart.
Semma Therapeutics aims to provide beta cells--the pancreatic cells that produce insulin--to patients with Type 1 diabetes. If the startup can get beyond early research, an implantable device that creates insulin via these stem cell-derived beta cells could replace daily insulin injections and transform patient care.
Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.
Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.
Miss Idaho is trending, but it has nothing to do with pageantry. The hashtag "show me your pump" became popular after newly crowned Sierra Sandison, diagnosed with Type I diabetes in 2012, was spotted on stage with her insulin pump by her side.
Following a lengthy waiting period for FDA approval, Animas--Johnson & Johnson's diabetes division--launched its newest combination insulin pump and continuous glucose monitoring device in Canada.
Insulin pump treatments worked better than injections to boost glycemic control in children with Type 1 diabetes, a new observational study out of Australia concluded.